Abstract:Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss.1 Numerous treatment options are available for AA.2, 3 However, it is often challenging and unsatisfactory for refractory AA treatment. Recently, Janus kinase inhibitors (JAKis) have shown promising results in treating AA.4 For example, baricitinib has shown good clinical efficacy in two phase 3 trials involving patients with severe AA.5 Here we present a case series of 11 patients with refractory AA treated with baricitinib. The Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine (Approved number: IIT2022089) approved this study. The following clinical characteristics were collected: age, sex, age at AA onset, disease duration, clinical type, previous treatment, and comorbidities. At each visit, symptom-directed physical examination and clinical laboratory tests were conducted. All patients received at least one therapy for more than 1 year, including minoxidil, oral/topical/intralesional steroid, phototherapy, acupuncture, or herbal medicine prior to the initiation of baricitinib; however, the response was poor. All patients received baricitinib 2 mg twice daily for 20 weeks. Meanwhile, patients also used topical minoxidil as adjuvant therapy. The Severity of Alopecia Tool (SALT) was used to assess alopecia severity. SALT25, SALT50, and SALT75 were defined as 25%, 50%, and 75% regrowth, respectively. The results were divided into the following three categories: (I) “complete response” (CR), hair growth coexisted with no obvious plaques of hair loss; (II) “partial response” (PR), hair growth coexisted with obvious plaques; and (III) “no response” (NR), no hair growth. Adverse events were also recorded. The results are summarized in Table 1. The subtypes of AA included alopecia universalis in two patients, alopecia totalis in two patients, multiple AA in six patients, and alopecia ophiasis in one patient. The median age at the beginning of AA was 17 (range, 3–14) and the median baseline SALT score was 54% (range, 32%–100%). Seven patients (64%) had nail involvement and five (45%) patients had total or partial body hair loss. At week 20, two patients (18%) achieved CR, six patients (55%) achieved PR, and three patients (27%) were evaluated as NR. Nine patients responded positively to baricitinib treatment, one of whom subsequently lost regenerated hair, while the other two patients experienced no regrowth. The median SALT score was 15% (range, 3%–100%) and the median percent change in SALT score was 34% (range, 0%–83%) at week 20. Our results showed that seven patients (64%), three patients (27%), and two patients (18%) achieved SALT25, SALT50, and SALT75, respectively, while none of them achieved complete hair regrowth. Representative photos of two patients who had a typical response to baricitinib therapy are presented in Figure 1. Adverse events were mild and limited to nausea (n = 1), folliculitis (n = 2), and mild increases in liver transaminase levels (n = 1). A meta-analysis estimated that 72.4% of patients with AA responded to JAKis.6 Furthermore, one phase 2 trial7 and two phase 3 trials5 demonstrated that baricitinib 4 mg once daily proved beneficial over the 2-mg dose. In our study, 27% achieved SALT50 with twice-daily oral baricitinib at a 2-mg dose, which is a remarkable finding because most patients had refractory AA. This series included only Chinese patients and they received a different dose of baricitinib because some patients were unable to tolerate the gastrointestinal reactions at a 4-mg dose once daily. Further investigations are needed in the future to explore whether this difference in baricitinib response is due to ethnic or environmental differences. Moreover, numerous studies described an increased serum level of IL-6 and IL-17A in patients with AA.8, 9 Indeed, serum level of IL-6 and IL-17A was significantly elevated in 54.5% of all patients at the baseline in our study. After treatment with baricitinib, both levels returned to normal. In summary, in our study, baricitinib is efficacious in refractory AA treatment. To determine the safety and efficacy of baricitinib for AA, further trials are warranted. Study design: Yuqian Wang, Jianjun Qiao, Hong Fang. Data collection: Yuqian Wang, Taoming Liu, Sheng Li, Shunli Tang, Peiyi Lin, Yuwei Ding. Statistical analysis: Yuqian Wang. Data interpretation: Qingmiao Sun, Dingxian Zhu. Manuscript preparation: Yuqian Wang, Jianjun Qiao, Hong Fang. The authors wish to thank all patients who took part in this study. The patients in this manuscript have given written informed consent for publication of their case details. This study was supported by the National Natural Science Foundation of China (81972931 and 81673045 to HF). The authors have no conflicts to disclose in relation to the present study. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Successful baricitinib treatment of refractory anti‐synthetase syndrome associated with interstitial lung disease

Short-term Effectiveness of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis.

The Efficacy of Baricitinib in Real-World Patients with Refractory or Severe Juvenile Dermatomyositis:A Monocentric Retrospective Study

Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study

Efficacy and Safety of Baricitinib in Patients with Refractory Alopecia Areata

Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease

Tocilizumab Treatment in a Patient of Refractory Anti-EJ Positive ASyS: A Case Report

Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report

Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: Results from a Phase 3 Study.

Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study

Baricitinib is Potentially Effective in the Treatment of Refractory Livedoid Vasculopathy

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib

Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis

Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China

Baricitinib as a treatment for myasthenia gravis: a case report

Successful treatment of cutaneous polyarteritis nodosa with baricitinib

Natural history of indolent-anti-synthetase syndrome-associated interstitial lung disease

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor